# A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

Source: https://onco.cc/trials/nct06989437/  
OnCo record `nct06989437` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of ponsegromab in pancreatic ductal adenocarcinoma, run by Pfizer, now recruiting.

## Summary

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue is a phase 2/3 interventional study registered as NCT06989437 by Pfizer, with 982 participants planned, started 2025-10-03 and due to reach its primary completion in 2028-01-17. Interventions recorded: ponsegromab and placebo.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06989437
- Phase: 2/3
- Setting: A Phase 2b/3, Randomized, Double-Blind Study to Investigate the Efficacy, Safety, and Tolerability of Ponsegromab (PF-06946860) Compared With Placebo Both With Background First-Line Chemotherapy in Adult Participants With Cachexia and Metastatic Pancreatic Ductal Adenocarcinoma
- Sponsor: Pfizer
- Enrolled: 982

## Sources

- ClinicalTrials.gov NCT06989437: https://clinicaltrials.gov/study/NCT06989437

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- companies: [Pfizer (incl. Seagen)](https://onco.cc/companies/pfizer/)
- drugs: [Ponsegromab](https://onco.cc/drugs/ponsegromab/)

---
JSON: https://onco.cc/api/v1/entities/nct06989437.json